United Therapeutics Corporation announced that it has entered into an exclusive license agreement with privately held drug development company, Samumed LLC, for purchasing the North American rights to the latter’s IPF drug candidate, SM04646.
SUBSCRIBE
Biohealth Innovation
Founding Member of
